Mutation of Threonine 34 in Mouse Podoplanin-Fc Reduces CLEC-2 Binding and Toxicity in Vivo While Retaining Anti-lymphangiogenic Activity*

Received for publication, January 15, 2014, and in revised form, May 20, 2014. Published, JBC Papers in Press, June 6, 2014, DOI 10.1074/jbc.M114.550525

Roberta Bianchi1, Eliane Fischer9, Don Yuen6, Ellen Ernst4, Alexandra M. Ochsenbein4, Lu Chen9, Vivianne I. Otto6, and Michael Detmar5,7

From the 4Institute of Pharmaceutical Sciences, ETH Zurich, 8093 Zurich, Switzerland, the 6Center for Radiopharmaceutical Sciences, Paul Scherrer Institute PSI, 5232 Villigen, Switzerland, and the 7Center for Eye Disease and Development, Program in Vision Science and School of Optometry, University of California at Berkeley, Berkeley, California 94720

Background: Podoplanin-Fc inhibits lymphangiogenesis, but also causes a bleeding disorder by binding to CLEC-2 expressed on platelets.

Results: Mutation of threonine 34 in mouse Pdpn-Fc reduces 30-fold the binding to CLEC-2 and does not hamper its anti-lymphangiogenic activity.

Conclusion: PdpnT34A-Fc is an active lymphangiogenesis inhibitor with a better tolerability.

Significance: Mutagenesis of Pdpn-Fc is a valid approach to improve this tool for anti-lymphangiogenic therapy.

The lymphatic system plays an important role in cancer metastasis and inhibition of lymphangiogenesis could be valuable in fighting cancer dissemination. Podoplanin (Pdpn) is a small, transmembrane glycoprotein expressed on the surface of lymphatic endothelial cells (LEC). During mouse development, binding of Pdpn to the C-type lectin-like receptor 2 (CLEC-2) on platelets is critical for the separation of the lymphatic and blood vascular systems. Competitive inhibition of Pdpn functions with a soluble form of the protein, Pdpn-Fc, leads to reduced lymphangiogenesis in vitro and in vivo. However, the transgenic over-expression of human Pdpn-Fc in mouse skin causes disseminated intravascular coagulation due to platelet activation via CLEC-2. In the present study, we produced and characterized a mutant form of mouse Pdpn-Fc, in which threonine 34, which is considered essential for CLEC-2 binding, was mutated to alanine (PdpnT34A-Fc). Indeed, PdpnT34A-Fc displayed a 30-fold reduced binding affinity for CLEC-2 compared with Pdpn-Fc. This also translated into fewer side effects due to platelet activation in vivo. Mice showed less prolonged bleeding time and fewer embolized vessels in the liver, when PdpnT34A-Fc was injected intravenously. However, PdpnT34A-Fc was still as active as wild-type Pdpn-Fc in inhibiting lymphangiogenesis in vitro and also inhibited lymphangiogenesis in vivo. These data suggest that the function of Pdpn in lymphangiogenesis does not depend on threonine 34 in the CLEC-2 binding domain and that PdpnT34A-Fc might be an improved inhibitor of lymphangiogenesis with fewer toxic side effects.

The lymphatic vascular system has important physiological functions draining interstitial tissue fluid, transporting antigens and immune cells, and in the uptake of intestinal lipids. Moreover, the lymphatic system contributes to a number of pathological processes, such as cancer metastasis, inflammatory diseases, and transplant rejection. In pathological settings, the lymphatic system actively expands, a process called lymphangiogenesis. Inhibition of lymphangiogenesis has recently been proposed as a therapeutic approach for cancer therapy, as it may block the spread of cancer cells to the draining lymph node and beyond (1–3). Several molecules have been described to be important in the development, morphogenesis, and maintenance of lymphatic vessels, but so far only the antibody targeting of one of these molecules, vascular endothelial growth factor receptor 3, entered clinical trials (4).

Podoplanin (Pdpn)2 is an extensively O-glycosylated type-1 transmembrane protein expressed by lymphatic endothelial cells (LEC) (5), follicular reticular cells (6), kidney podocytes (7), and alveolar type-1 cells (8). Via its extracellular domain, Pdpn binds galectin-8 (9), CCL21 (10), and C-type lectin-like receptor 2 (CLEC-2) (11). CLEC-2 is a membrane-bound protein expressed by platelets (12), dendritic cells (13), and neutrophils (14). Binding of the snake venom rhodocytin or Pdpn to CLEC-2 on platelets triggers intracellular signaling via Syk-SLP76 that leads to platelet activation (15). The molecular interaction between Pdpn and CLEC-2 has been shown to be important in the development of the lymphatic system, as it is involved in the physical separation of the lymph sacs from the blood-filled cardinal vein (16, 17). Also, CLEC-2-positive dendritic cells interact with Pdpn-positive LEC and follicular reticular cells for their migration from the periphery to and through the lymph node where they present antigens to T-cells (18).

Very recently, the interaction between CLEC-2-positive platelet
lets and Pdpn-positive follicular reticular cells was reported to be involved in maintaining the integrity of high endothelial venules (19).

Given its expression on LEC but not on blood vascular endothelial cells and its pivotal role in the development of the lymphatic system, Pdpn has been considered a suitable target to inhibit lymphangiogenesis. A human Pdpn-Fc chimera has been shown to be an effective lymphangiogenesis inhibitor in vitro and in vivo (20). However, mice overexpressing Pdpn-Fc under control of the skin-specific keratin 14 promoter displayed a bleeding disorder, namely disseminated intravascular coagulation. Apparently, the Pdpn-Fc present in the serum of these mice interacted with endogenous CLEC-2 expressed by platelets and thereby caused disseminated intravascular coagulation (20).

Here, we aimed to generate a Pdpn-Fc that would actively inhibit lymphangiogenesis, but would lack platelet aggregation side effects, thereby improving its tolerability. To this end, we mutagenized threonine 34, which is located in the first platelet aggregation stimulating (PLAG) domain of Pdpn and has been described in Zuberbühler (22) and the hamster anti-mouse Pdpn antibody (clone 8.1.1) and a HRP-coupled secondary anti-hamster IgG antibody (Abcam).

**CLEC-2 Binding Assays—**CLEC-2 reporter cells (BWZ.36-CLEC-2/CD3) and dectin1 control reporter cells (BWZ.36-dectin1/CD3) were kindly provided by Prof. Gordon Brown (University of Aberdeen) and cultured as previously described (23, 24). CLEC-2 activation studies were performed as previously described (23, 25). Briefly, 24-well plates were pre-coated with a capturing rabbit anti-human IgG Fc antibody (50 μg/ml, Jackson ImmunoResearch), followed by incubation with mPdpn-Fc or mPdpnT34A-Fc (20 ng/ml). 3 × 10^5 reporter cells per well were added and incubated overnight. As a positive control of activation, reporter cells were cultured with 40 ng/ml of phorbol 12-myristate 13-acetate and 1.5 μg/ml of ionomycin. IL-2 released into the supernatant was quantified by ELISA (BD Pharmingen), and the cells were fixed and stained for β-galactosidase as previously described (23). For CLEC-2 binding studies, reporter cells were first incubated with an FcR blocking antibody (anti-CD16/32, Biolegend) for 30 min and then with 20 ng/ml of mPdpn-Fc isoforms or VEFR3-Fc (R&D Systems) for 1 h at 4 °C. After incubation with a secondary anti-human IgG Fc-specific antibody coupled with FITC (Jackson ImmunoResearch), samples were analyzed for specific binding in a fluorescence-activated cell sorter (BD FACS Canto). Median fluorescence intensity for FITC was analyzed using FlowJo software. For competition assays and IC_{so} calculation, 100 μg of wild-type mPdpn-Fc was radiolabeled with 125I (PerkinElmer Life Sciences) using the IODO-GEN method and purified on a PD-10 column (GE Healthcare) as previously described (26). CLEC-2 reporter cells (1.2 × 10^5) were incubated with 75 ng (2 nM) of radiolabeled tracer and increasing concentrations of unlabeled competitor (mPdpn-Fc WT or mPdpnT34A-Fc) for 2 h at 4 °C. Cells were washed twice with PBS and cell bound radioactivity in counts per minute (cpm) was measured in a γ counter and the data were plotted in GraphPad Prism software. The data were fitted using the nonlinear regression and IC_{so} for the two competitors was calculated using GraphPad Prism.

**In Vitro Assays with Lymphatic Endothelial Cells—**Immortalized mouse lymphatic endothelial cells (imLEC) were provided by Prof. Cornelia Halin (ETH Zurich) and cultured as described (27). Adhesion assays were performed as previously described (28). Briefly, 96-well cell culture plates were coated with type I collagen (50 μg/ml), 6 × 10^4 calcein-labeled imLEC
per well were incubated for 20 min at 37 °C in the presence or absence of 0.5 μM mPdpn-Fc isoforms or human IgG control (Sigma). Fluorescence was measured using a SpectraMax microplate reader (Molecular Devices). Haptotaxis assays were performed using transwells (pore size 8 μm; Costar), which were coated with 50 μg/ml of type I collagen on the bottom side. IMLEC (103/30) were allowed to migrate for 3 h at 37 °C with 0.5 μM mPdpn-Fc isoforms or human IgG added to both the upper and lower compartment. Three (migration) or 8 (adhesion) replicates were performed, and the statistical significance of the data were analyzed using one-way analysis of variance with a Dunnett post test.

In Vivo Cornea Lymphangiogenesis Assay—Inflammatory lymphangiogenesis was induced in the cornea of BALB/c mice by suture placement as described previously (29). All protocols were approved by the University of California at Berkeley, Animal Care and Use Committee, and animals were treated according to the Association for Research in Vision and Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision Research. Mice were anesthetized using a mixture of ketamine, xylazine, and acepromazine (50, 10, and 1 mg/kg body weight, respectively) for each surgical procedure. Seventy micrograms of mPdpn-Fc isoforms or human IgG (Sigma) were injected into the subconjunctival space twice a week for 2 weeks after suture placement. Then, corneas were excised, lymphatic and blood vessels were visualized by immunofluorescent staining for LYVE-1 (Abcam) and CD31 (Santa Cruz). The samples were observed with an Axioplan 2 epifluorescence microscope (Zeiss) and photographed with an Axiocam digital camera system (Zeiss). Corneal blood and lymphatic vessels were analyzed using NIH Image software, as described previously (29). Vascular structures stained as CD31+/LYVE-1+ were identified as blood vessels, whereas those stained as CD31+/LYVE-1− were defined as lymphatic vessels. The percentage scores of LG coverage areas were obtained by normalizing to control groups where the lymphatic coverage areas were defined as being 100%. The results are reported as mean ± S.E. and Mann-Whitney test was used for the determination of significance levels between different groups using Prism software (GraphPad). The differences were considered statistically significant when p < 0.05.

Developmental Diaphragm Lymphangiogenesis Assay—Animal experiments were performed complying with the animal protocols approved by the local veterinary authorities (Kantonales Veterinäramt Zürich). Pregnant mice (C57Bl6/J, Charles River) were injected intraperitoneally at 16.5 and 18.5 days postcoitum, corresponding to embryonic day (E) 16.5 and 18.5, with mPdpnT34A-Fc or IgG control (100 μg/dose). Pups (6–7 per litter) were analyzed at postnatal day 5. The diaphragm was dissected, fixed in 4% paraformaldehyde, washed with PBS, and incubated in blocking solution (5% normal donkey serum, 1% BSA, 0.1% Triton X-100, 0.05% sodium azide). Primary antibody against LYVE-1 (AngioBio) was incubated overnight in blocking solution. After extensive washes in PBS, samples were incubated with Alexa-coupled secondary antibody (Invitrogen). Diaphragms were flat mounted with Vectashield mounting medium (Vector Laboratories). Two diaphragmatic branches per mouse where imaged, using a confocal microscope (Zeiss LSM 710-FCS) equipped with a 10×0.3 NA EC Plan-Neofluar objective. The total LYVE-1 positive area, number of branches, and branch length were analyzed using ImageJ software.

Bleeding Time Measurement, Blood and Tissue Analysis—Ten- to 12-week-old female FVB mice were injected intravenously (tail vein) with 1 μg of mPdpn-Fc isoforms or human IgG control (Sigma). Six hours after injection, mice were deeply anesthetized and 5 mm of the tail were cut with a scalpel blade. Bleeding time was monitored by placing the cut tail into warm PBS. At the time of bleeding cessation, or after 60 min, mice were sacrificed and serum was collected for analysis. After withdrawing blood by cardiac puncture and body perfusion with PBS, livers were fixed in 4% paraformaldehyde overnight at 4 °C and subsequently impregnated in 30% sucrose for 48 h. Organs were then embedded in OCT. Five-μm cryosections were immunostained for red blood cells (RBC) (Ter119 antibody, eBioscience) or platelets (CD41, BD Biosciences). The RBC and platelet−stained area were analyzed in five ×10 or 20 magnified images per section using ImageJ software. Pdpn-Fc levels in serum samples were analyzed by capture ELISA. Briefly, maxisorp 96-well plates (NUNC) were coated with 100 ng/ml of rabbit anti-human Fc capturing antibody in PBS (Jackson ImmunoResearch) for 1 h at 37 °C. After 1 h of blocking with 1% FCS in PBS, standards and diluted serum samples were added for 1 h at 37 °C. Plates were washed three times with 0.05% Tween in PBS and then incubated with the hamster anti-mouse Pdpn (clone 8.11) antibody followed by an HRP-coupled anti-hamster IgG antibody. For detection, the BM blue POD substrate (Roche Applied Science) was used following the manufacturer’s instructions. The standard curve was analyzed using a four-parameter logistic fit.

Ex Vivo FACS Analysis of Platelet Activation—Blood was withdrawn from deeply anesthetized FVB wild-type female mice via cardiac puncture and mixed 1:10 with ACD anticoagulant (acid-citrate-dextrose, Sigma). Whole blood was diluted in modified Tyrode’s buffer (137 mM NaCl, 20 mM HEPES, 2.7 mM KCl, 3.3 mM NaH2PO4, 5.6 mM glucose, 1 g/liter of BSA, 1 mM MgCl2, 1 mM CaCl2) plus 1 mM GPRP peptide (PEFA-block, Pentapharm) and incubated for 1 h with mPdpn-Fc isoforms (100 ng) in the presence of an anti-human Fc cross-linking antibody (Jackson ImmunoResearch) or with thrombin (0.2 unit, Sigma) as a positive control of activation. Activated blood was stained with the following antibodies: anti-CD41-APC (Biology), anti-activated integrin αIIbβ3-PE (clone JON/A, Emfret Analytics), and anti-CD62p-FITC (clone Wug.E9, Emfret Analytics). Samples were acquired with a fluorescence activated cell sorter (FACS Canto, BD Biosciences) and data were analyzed with FlowJo software.

RESULTS

Characterization of Two Recombinant Mouse Podoplanin-Fc Isoforms, mPdpn-Fc and mPdpnT34A-Fc—We previously reported that human podoplanin-Fc acts as a lymphangiogenesis inhibitor in vitro and in vivo (20). However, its transgenic overexpression in mouse skin causes disseminated intravascular coagulation due to its capacity to activate platelets and induce platelet aggregation via CLEC-2. To circumvent this side effect, we cloned a mouse Pdpn-Fc chimera and mu-
tagenized threonine 34 to alanine (T34A), attaining the mPdpnT34A-Fc isoform (Fig. 1A).

Both recombinant proteins were expressed in CHO cells and purified by protein A affinity chromatography. Analysis by SDS-PAGE and silver staining, immunoblot, and gel filtration chromatography revealed that the recombinant proteins were pure, immunoreactive for Pdpn, and dimeric with the monomers linked through disulfide bridges (Fig. 1B–D).

Digestion with neuraminidase followed by O-glycosidase (Fig. 1E) showed that both recombinant proteins were sialylated and decorated with core-1 O-glycans. Moreover, the extent of sialylation and O-glycosylation was comparable with one of the endogenous podoplanin expressed by imLEC. The recombinant proteins and endogenous Pdpn appeared to also be N-glycosylated. Digestion with peptide N-glycosidase F revealed that the recombinant proteins as well as the endogenous LEC Pdpn were also N-glycosylated (Fig. 1F).

**FIGURE 1.** Characterization of two recombinant mouse podoplanin Fc chimera isoforms, mPdpn-Fc and mPdpnT34A-Fc. A, a schematic representation of mPdpn-Fc and mPdpnT34A-Fc. B, recombinant mPdpn-Fc isoforms were produced in CHO cells, affinity purified using Protein A and samples were resolved by SDS-PAGE under reducing (r) or non-reducing (nr) conditions. Silver staining revealed that both proteins were >95% pure. C, both isoforms were stained by an antibody directed against mouse podoplanin in Western blot and were present as disulfide-linked dimers. D, purified proteins were analyzed by gel filtration chromatography on a Superdex 200 10/30 column. They eluted as single species. E, to characterize their glycosylation, purified mPdpn-Fc and mPdpnT34A-Fc as well as the cell lysate of mouse immortalized LEC (imLEC) were digested with neuraminidase (Neu) followed by O-glycosidase (O-gly), F, to test for the presence of N-glycans, digestion was performed with peptide N-glycanase F (PNGase F). Samples were resolved by SDS-PAGE and immunoblotted with an anti-mouse Pdpn antibody (E and F). Both isoforms were sialylated and decorated with core-1 O-glycans. Moreover, the extent of sialylation and O-glycosylation was comparable with one of the endogenous podoplanin expressed by imLEC. The recombinant proteins and endogenous Pdpn appeared to also be N-glycosylated.

**mPdpnT34A-Fc as an Improved Lymphangiogenesis Inhibitor**

To test the CLEC-2 binding and activation ability of the two mPdpn-Fc isoforms, we utilized CLEC-2 reporter cells (BWZ.36 CLEC-2/CD11c) and dectin1 reporter cells (BWZ.36 dectin1/CD11c) expressing a control C-type lectin receptor (24). This cellular reporter system is based on BWZ.36 cells as described by others (30). Briefly, BWZ.36 cells were transduced to express a chimeric CLEC-2/CD11c receptor, or a control dectin1/CD11c chimeric receptor. Ligand binding to CLEC-2 or dectin1 induces signaling through the CD11c cytoplasmic tail, and the expression of β-galactosidase and IL-2. We found that mPdpn-Fc potently activated CLEC-2 reporter cells as shown by both X-gal staining (Fig. 2A)
and IL-2 secretion into the supernatant (Fig. 2B). However, CLEC-2 activation by mPdpnT34A-Fc was significantly reduced as evidenced by weaker X-gal staining and lower IL-2 secretion. The binding of both mPdpn-Fc isoforms was specific to CLEC-2, because no activation was observed in dectin1 control reporter cells. Binding to CLEC-2 was also assessed by flow cytometry (Fig. 2C). Also in this setting, mPdpn-Fc specifically bound to CLEC-2 on the surface of the reporter cells. mPdpnT34A-Fc displayed a significantly reduced ability to bind the receptor, as quantified by Δ median fluorescence intensity (ΔMFI, Fig. 2D).

**IC**\(_{50}\)** of mPdpnT34A-Fc for CLEC-2 Was Reduced 30-Fold Compared with mPdpn-Fc—To study the interaction between mPdpn-Fc isoforms and CLEC-2 quantitatively, we radiolabeled mPdpn-Fc with iodine 125 and performed competitive binding measurements on CLEC-2 expressing cells with increasing doses of unlabeled mPdpn-Fc and mPdpnT34A-Fc (Fig. 3A). As shown in Fig. 3B, mPdpn-Fc bound to CLEC-2 with an IC\(_{50}\) of 2.2 nM (confidence interval 95%, 1.7 to 2.9 nM). The affinity of mPdpnT34A-Fc was 30 times lower, with an IC\(_{50}\) of 69.5 nM (confidence interval 95%, 50.7 to 95.3 nM). Taken together, these data indicate that the T34A mutation does not completely abolish the ability of Pdpn to bind to CLEC-2.

**mPdpnT34A-Fc Retained Full Ability to Inhibit Lymphangiogenesis in Vitro and in Vivo**—Human Pdpn-Fc was shown to be a lymphangiogenesis inhibitor (20). Here, we compared the anti-lymphangiogenic activity of mPdpn-Fc and mPdpnT34A-Fc using two in vitro assays that mimic crucial steps in the formation of new lymphatic vessels, namely the ability of LEC to adhere and to migrate in the extracellular matrix. Both proteins were tested in vitro using imLEC and found to significantly inhibit LEC adhesion to collagen type I (Fig. 4A) and LEC migration toward collagen type I (Fig. 4B). In both assays, no significant difference was observed between the two Pdpn-Fc isoforms. Threonine 34 appears therefore not to be essential for the anti-lymphangiogenic activity of mPdpn-Fc in vitro.

We then investigated the anti-lymphangiogenic activity of mPdpn-Fc isoforms in two in vivo models of lymphangiogenesis that better represent the complexity of the whole lymphangiogenic process. In the first model, three sutures were placed into the mouse cornea, which is normally devoid of blood vessels and lymphatic vessels. The sutures serve as an inflammatory stimulus to trigger the growth of both blood and lymphatic vessels. After suture placement, mice received mPdpn-Fc, mPdpnT34A-Fc, or human IgG control by subconjunctival injection twice a week for 2 weeks. Surprisingly, 80% of the mice...
treated with mPdpn-Fc died after the first injection (Fig. 5A), displaying signs of pulmonary embolism (difficulties in breathing and recovering from anesthesia). After 2 weeks, the remaining mice in the mPdpnT34A-Fc and human IgG groups were sacrificed and their corneas stained for the lymphatic marker LYVE-1 (Fig. 5B). The area covered by invaded lymphatic vessels was quantified. Mice treated with mPdpnT34A-Fc had a significantly smaller lymphatic vessel invasion area in the cornea, compared with human IgG control (Fig. 5C). In contrast, the treatments did not influence blood vessel invasion (not shown). mPdpnT34A-Fc is therefore an active lymphangiogenesis inhibitor in vivo, which does not provoke pulmonary embolisms and thus lacks the potent toxic effect of mPdpn-Fc. In a second in vivo model of lymphangiogenesis, we took advantage of the fact that the lymphatic network in the mouse diaphragm develops during embryogenesis and the early postnatal days. Mouse embryos where treated at E16.5 and E18.5 with either mPdpnT34A-Fc or hIgG control, which were injected intraperitoneally into the pregnant mother. At this point in development, the lymphatic system was already separated from the cardinal vein, and the lymphatic plexuses are expanding in peripheral organs. Pups where analyzed at postnatal day 5. The mPdpnT34A-Fc was detected in the serum of the pups by ELISA (data not shown), indicating that the recombinant protein was transported through the placenta. The lymphatic network in the diaphragm of the mPdpnT34A-Fc-treated pups appeared less complex than that of the control treated animals when whole mount preparations were stained for LYVE-1 (Fig. 5D). Morphometric analyses revealed a reduced number of branches (Fig. 5E) and a higher average branch length (Fig. 5F) despite a comparable total LYVE-1 positive area (Fig. 5F). This suggests that upon mPdpnT34A-Fc treatment, a less complex lymphatic network develops, characterized by fewer and longer branches. Taken together, the present data show that mPdpnT34A-Fc inhibits inflammatory as well as developmental lymphangiogenesis in vivo.

mPdpnT34A-Fc Displayed Reduced Toxicity and Reduced Ability to Induce Platelet Aggregation in Vivo—We next evaluated the toxic effect of mPdpn-Fc on mice more closely. Mice were injected intravenously with mPdpn-Fc, mPdpnT34A-Fc, or human IgG control. Six hours afterward, bleeding time was measured by tail clipping. 80% of the mice that had received mPdpn-Fc did not stop bleeding after 60 min (Fig. 6A). In those mice, we observed embolized vessels in the liver as assessed by immunostaining for red blood cells (RBC) (Fig. 6, C and D) and for platelets (CD41, Fig. 6, E and F). Conversely, only half of the mice that had received mPdpnT34A-Fc displayed prolonged bleeding times. The area covered by the embolized vessels and the extent of platelet deposition in their livers was comparable among all mice as measured by ELISA (Fig. 6B). In particular, they were similar between the treatment groups and there was no correlation between serum concentration and bleeding time (not shown). To test a direct effect of mPdpn-Fc isomers on platelet activation, we incubated mouse whole blood with...
recombinant proteins in the presence of a cross-linking anti-human Fc antibody, and analyzed the levels of the activation markers integrin αIIbβ3 (active form, Fig. 7A) and CD62p on platelets by FACS (Fig. 7B). The mPdpnT34A-Fc had a significantly reduced ability to induce both activation markers and therefore to activate platelets ex vivo. Collectively, our data suggest that mPdpnT34A-Fc induced less platelet activation, therefore provoked fewer embolized liver vessels and fewer bleeding abnormalities in mice making it a significantly less toxic agent than mPdpn-Fc.

**DISCUSSION**

Lymphatic vessels play critical roles in the physiologic maintenance of fluid homeostasis. However, formation of new lymphatic vessels may contribute to pathological conditions, for instance, by favoring cancer spread and metastasis. Under such circumstances, inhibition of lymphangiogenesis may be clinically valuable. Pdpn, a mucin-type glycoprotein typically expressed on lymphatic endothelial cells and a major player in lymphatic development, has been proposed as a suitable target for modulation of lymphangiogenesis. Blocking Pdpn by means of a soluble form of its ectodomain, the Pdpn-Fc chimera, led to inhibition of lymphangiogenesis. However, its overexpression in mouse skin provoked disseminated intravascular coagulation due to the interaction of Pdpn-Fc with CLEC-2 expressed on platelets (20).

Here, we aimed at generating an improved mouse Pdpn-Fc chimera that would lack CLEC-2 related toxicity while retaining anti-lymphangiogenic activity by mutagenizing threonine 34, a residue reported to be crucial for CLEC-2 binding (21). We produced and purified two mPdpn-Fc isoforms using CHO cells and protein A affinity chromatography. With regard to the
types of glycans present, the two mPdpn-Fc chimeras appeared comparable with endogenous Pdpn expressed by mouse LEC. Neuraminidase and O-glycanase digests revealed the presence of large amounts of sialylated core-1 O-glycans. Both mPdpn-Fc isoforms as well as the natural Pdpn of mouse LECs appeared to additionally carry some N-glycan as evidenced by peptide N-glycosidase F digestion. There is one potential site of N-glycosylation in the ectodomain of mouse Pdpn, and another in the human Fc domain of the recombinant proteins. In a previous analysis, Scholl et al. (31) assessed the O- and N-glyco-

FIGURE 6. mPdpnT34A-Fc displays reduced toxicity and a reduced ability to induce platelet aggregation in vivo. A, FVB mice received either 1 μg of mPdpn-Fc isoforms or hIgG control by tail vein injection. Six hours later, the tail was clipped and bleeding time was measured. Only 50% of the mice treated with mPdpnT34A-Fc displayed abnormal bleeding (>60 min), whereas 80% of the mice that received mPdpn-Fc bled abnormally. B, serum levels of circulating mPdpn-Fc isoforms at 6 h after injection of 1 μg of protein were assessed by capture ELISA and found to be comparable between the two groups. C, frozen sections of livers were stained for red blood cells (RBC) to visualize embolized vessels. The autofluorescence of the liver is shown in green fluorescence channel. D, the RBC-positive area was quantified with ImageJ. The area covered by RBC-positive blood clots was significantly lower in the livers of mice treated with mPdpnT34A-Fc than in mice treated with mPdpn-Fc. E, frozen sections of livers were stained for platelets (CD41) to visualize platelet deposition. The autofluorescence of the liver is shown in the green fluorescence channel and DAPI was used to visualize the nuclei. F, the CD41-positive area was quantified with ImageJ. The area covered by CD41-positive platelets was significantly lower in the livers of mice treated with mPdpnT34A-Fc than in mice treated with mPdpn-Fc. Scale bar, 100 μm. Data represent mean ± S.E.; statistical significance was analyzed using the one-way analysis of variance and a Dunnett post test. *** p < 0.001.
The reduction appeared somewhat smaller in the FACS-based binding assay (Fig. 2D) and in the assay measuring IL-2 secretion induced upon engagement of CLEC-2 by mPdpn-Fc (Fig. 2B). However, the competitive radio-labeled assay was performed titrating the dose of inhibitors, whereas the other assays tested binders at a single dose. The competitive binding assay is thus the only assay that has the power to measure quantitatively a difference in binding that was already observed in the other two assays performed. Collectively, our data suggest that elimination of threonine 34 and possibly an O-glycan, which may be attached to it, is not sufficient to abolish binding to CLEC-2 as previously described by Kato et al. (21). However, our experimental setting clearly differed from the one chosen by Kato and colleagues (21). We used soluble Pdpn-Fc chimera interacting with CLEC-2 expressed on the cell membrane of reporter cells, whereas Kato et al. (21) used Pdpn mutants expressed at the surface of CHO cells interacting with platelet-rich plasma. We measured binding, whereas Kato et al. (21) measured platelet activation. However, it appears that threonine 34 and/or a potential threonine 34-bound O-glycan contribute to CLEC-2 binding. It can thus be speculated that the CLEC-2 binding domain of Pdpn may be larger, comprising additional parts of the protein and/or other glycans. Such a binding domain comprising not only a threonine-linked O-glycan but also several residues of the underlying protein has been reported for the C-type lectin P-selectin (33). Its binding site on P-selectin glycoprotein ligand-1 comprises, in addition to the sialylated and fucosylated core-2 O-glycan linked to threonine 47, three sulfated tyrosine residues (Tyr-46, Tyr-48, and Tyr-51) and several negatively charged amino acids. Whereas both the glycan and the underlying peptide are essential for binding, the three tyrosine sulfates contribute to binding, increasing the affinity 30-fold (33). Alternatively, there may be additional CLEC-2 binding sites on Pdpn. For instance, the ectodomain of Pdpn comprises not only one PLAG domain, but three tandem repeats, and the role of PLAG-2 and PLAG-3 has not been fully elucidated (34). Moreover, there are also reports indicating that the C-terminal region of Pdpn is necessary for its strong interaction with CLEC-2 (35). Some C terminally truncated mutants of the extracellular part of Pdpn fused to Fc failed to bind CLEC-2 despite intact PLAG domains (35). We therefore conclude that other residues besides threonine 34 and other parts of the protein may also be involved in the interaction between Pdpn and CLEC-2.

Independently of the presence or absence of threonine 34 and/or the O-glycan it may carry, Pdpn-Fc potently inhibited lymphangiogenesis when tested in functional LEC assays. Indeed, both Pdpn-Fc and PdpnT34A-Fc similarly and significantly inhibited adhesion and migration of LEC to collagen type I in vitro. Both Pdpn-Fc isoforms presumably act by interfering with the function of endogenous Pdpn expressed on LEC, blocking its interaction with an as yet unknown ligand. Knockdown of Pdpn on LEC has been shown to inhibit LEC adhesion to collagen type I, whereas up-regulation of Pdpn in EOMA cells stimulated their migration toward collagen and fibronectin (36). Collectively, these data suggest a role for Pdpn in LEC adhesion and migration, two key processes in the formation of new lymphatic vessels from pre-existing vessels. Also in other

**FIGURE 7.** mPdpnT34A-Fc displays reduced ability to induce platelet activation ex vivo. A, whole blood was incubated with mPdpn-Fc isoforms in the presence of a cross-linking anti-Fc antibody. Anti-Fc antibody alone and thrombin served as negative and positive controls, respectively. CD41-positive platelets were gated and analyzed for the expression of activated integrin αIIbβ3 (A) and CD62p (B), markers of platelet activation and degranulation, respectively. Median fluorescence intensity was calculated with FlowJo. mPdpnT34A-Fc had a reduced ability to activate platelets ex vivo. Data represent mean ± S.E.; statistical significance was analyzed using the unpaired 2-t student’s t test, **, p < 0.01; ***, p < 0.001.

sylation profiles of Pdpn derived from a mouse carcinoma cell line (PDV) and did not detect any N-linked glycans. This difference in findings may either be due to the small impact of single N-glycans on apparent molecular weight or point to a cell-specific difference in N-glycosylation of Pdpn. It is possible that a differential glycosylation might play a role in the regulation of the multiple, cell-specific functions of this versatile molecule.

Pdpn binds CLEC-2 via its extracellular domain and this interaction mediates platelet aggregation and dendritic cell migration (32). Kato and colleagues (21) identified a conserved octapeptide sequence within the Pdpn ectodomain, which they called PLAG domain as it appeared to be crucial for the platelet aggregation-inducing effect of Pdpn. Namely, they showed that CHO cells expressing a mutated form of mouse Pdpn in which threonine 34 within the first PLAG domain was replaced by alanine (PdpnT34A) failed to induce platelet aggregation in platelet-rich plasma. Based on these findings, we mutagenized threonine 34 of mouse Pdpn-Fc to alanine in an attempt to improve its tolerability. Surprisingly, we only observed a reduction in binding to CLEC-2 reporter cells, but not a complete abolishment in three different binding assays. The reduced binding corresponded to a 30-fold reduction of the IC_{50} when measured by a competitive binding assay using [^{125}I]Pdpn-Fc. 

*JOURNAL OF BIOLOGICAL CHEMISTRY* VOLUME 289 • NUMBER 30 • JULY 25, 2014 21024
of threonine 34 and the removal of the potentially attached O-glycan does not hamper the anti-lymphangiogenic activity of Pdpn-Fc, suggesting that the function of Pdpn in lymphangiogenesis does not depend on this residue. By reducing the interaction between Pdpn and CLEC-2 30-fold, however, mutation of threonine 34 improves its tolerability. As the toxicity related to CLEC-2 binding and platelet activation could not be fully abolished, it would be of interest to explore additional measures to further reduce toxicity. Previous studies of human Pdpn revealed that a short version of the molecule, comprising only the 2nd and 3rd PLAG domains and carrying a disialyl core-1 O-glycan, did bind CLEC-2 but did not induce platelet aggregation. Indeed, only a full-length, 128-amino acid version of human podoplanin efficiently induced platelet aggregation (35). Furthermore, a non-glycosylated version of human Pdpn-Fc retained the ability to inhibit lymphangiogenesis in vitro (20), but non-sialylated human Pdpn did not induce platelet aggregation (41). Therefore, C terminally shortened and non-glycosylated versions of mouse Pdpn-Fc should be tested in future studies for their anti-lymphangiogenic and platelet activating properties. Such studies will be of great importance to further improve our understanding of the role of other amino acids, other parts, and the glycosylation of mouse Pdpn for to further reduce toxicity. Previous studies of human Pdpn revealed that a short version of the molecule, comprising only the 2nd and 3rd PLAG domains and carrying a disialyl core-1 O-glycan, did bind CLEC-2 but did not induce platelet aggregation. Indeed, only a full-length, 128-amino acid version of human podoplanin efficiently induced platelet aggregation (35). Furthermore, a non-glycosylated version of human Pdpn-Fc retained the ability to inhibit lymphangiogenesis in vitro (20), but non-sialylated human Pdpn did not induce platelet aggregation (41). Therefore, C terminally shortened and non-glycosylated versions of mouse Pdpn-Fc should be tested in future studies for their anti-lymphangiogenic and platelet activating properties.

Acknowledgments—We thank Prof. Gordon Brown for providing CLEC-2 and dectin1 reporter cells, Prof. Cornelia Halin, Prof. Sabine Werner, Prof. Donto Scherzer, and Prof. Roger Schibli for helpful discussions, Susan Cohrs for precious technical assistance, Dr. Oliver Speer and Dr. Lothar Dieterich for advice on the platelet assay, and Thomas List for help with gel filtration chromatography.

REFERENCES

1. Cueni, L. N., and Detmar, M. (2008) The lymphatic system in health and disease. Lymphat. Res. Biol. 6, 109–122.
2. Alitalo, K. (2011) The lymphatic vasculature in disease. Nat. Med. 17, 1371–1380.
3. Tammela, T., and Alitalo, K. (2010) Lymphangiogenesis: molecular mechanisms and future promise. Cell 140, 460–476.
4. Alitalo, A., and Detmar, M. (2012) Interaction of tumor cells and lymphatic vessels in cancer progression. Oncogene 31, 4499–4508.
5. Breiteneder-Geleff, S., Soleiman, A., Kowalski, H., Horvath, R., Amann, G., Kriehuber, E., Diekm, K., Wening, W., Tschachler, E., Alitalo, K., and Kerjaschki, D. (1999) Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. Am. J. Pathol. 154, 385–394.
6. Farr, A. G., Berry, M. L., Kim, A., Nelson, A. J., Welch, M. P., and Aruffo, A. (1992) Characterization and cloning of a novel glycoprotein expressed by stromal cells in T-dependent areas of peripheral lymphoid tissues. J. Exp. Med. 176, 1477–1482.
7. Breiteneder-Geleff, S., Matsui, K., Soleiman, A., Meraner, P., Poczewski, H., Kalt, R., Schaffner, G., and Kerjaschki, D. (1997) Podoplanin, novel
43-kDa membrane protein of glomerular epithelial cells, is down-regulated in puromycin nephropathy. *Am. J. Pathol.* **151**, 1141–1152.

8. Williams, M. C., Cao, Y., Hinds, A. K., Rishi, A. K., and Wetterwald, A. (1996) T1α protein is developmentally regulated and expressed by alveolar type I cells, chordoid plexus, and ciliary epithelia of adult rats. *Am. J. Respir. Cell Mol. Biol.* **14**, 577–585.

9. Cueni, L. N. and Detmar, M. (2009) Galectin-8 interacts with podoplanin and modulates lymphatic endothelial cell functions. *Exp. Cell Res.* **315**, 1715–1723.

10. Kerjaschki, D., Regele, H. M., Moosberger, I., Nagy-Bojarski, K., Watschinger, B., Soleiman, A., Birner, P., Krieger, S., Hovorka, A., Silberhuber, G., Laakkonen, P., Petrova, T. R., Langer, B., and Raab, I. (2004) Lymphatic neoangiogenesis in human kidney transplants is associated with immunologically active lymphatic infiltrates. *J. Am. Soc. Nephrol.* **15**, 603–612.

11. Suzuki-Inoue, K., Kato, Y., Inoue, O., Kaneko, M. K., Mishima, K., Yatomi, Y., Yamazaki, Y., Narimatsu, H., and Ozaki, Y. (2007) Involvement of the snake toxin receptor CLEC-2 in podoplanin-mediated platelet activation, by cancer cells. *J. Biol. Chem.* **282**, 25993–26001.

12. Suzuki-Inoue, K., Fuller, G. L., García, A., Ebele, J. A., Pohlmann, S., Inoue, O., Gartner, T. K., Hughan, S. C., Pearce, A. C., Laing, G. D., Theakston, R. D., Schweighoffer, E., Zittmann, N., Morita, T., Tybulewicz, V. L., Olszewski, P., and Watson, S. P. (2006) A novel Syk-dependent mechanism of platelet activation by the C-type lectin receptor CLEC-2. *Blood* **107**, 542–549.

13. Colonna, M., Samaridis, J., and Angman, L. (2000) Molecular characterization of two novel C-type lectin-like receptors, one of which is selectively expressed in human dendritic cells. *Eur. J. Immunol.* **30**, 697–704.

14. Kerrigan, A. M., Dennehy, K. M., Mourão-Sá, D., Faro-Trindade, I., Willment, J. A., Taylor, P. R., Ebele, J. A., Reis e Sousa, C., and Brown, G. D. (2009) CLEC-2 is a phagocytic activation receptor expressed on murine peripheral blood neutrophils. *J. Immunol.* **182**, 4150–4157.

15. Suzuki-Inoue, K., Inoue, O., and Ozaki, Y. (2011) The novel platelet activation receptor CLEC-2. *Platelets** **22**, 380–384.

16. Uhrin, P., Zaujec, J., Breuss, J. M., Olcaydu, D., Chrenk, P., Stockinger, H., Pfaffer, E., Mozer, M., Haiko, P., Fassler, R., Alitalo, K., Binder, B. R., and Kerjaschki, D. (2010) Novel function for blood platelets and podoplanin in developmental separation of blood and lymphatic circulation. *Blood* **115**, 3997–4005.

17. Bertozzi, C. C., Schmaier, A. A., Mericko, P., Hess, P. R., Cao, Y., Hinds, A., Di Blasi, C., Silberhuber, G., Laakkonen, P., Petrova, T. R., Langer, B., and Raab, I. (2004) Lymphatic neoangiogenesis in human kidney transplants is associated with immunologically active lymphatic infiltrates. *J. Am. Soc. Nephrol.* **15**, 603–612.

18. Cueni, L. N., Detmar, M., and Kerjaschki, D. (2010) Novelist function for blood platelets and podoplanin in specific separation of blood and lymphatic circulation. *Am. J. Clin. Invest.* **119**, 54–61.

19. Herzog, B., Fu, J., Wilson, S. J., Hess, P. R., Sen, A., McDaniel, J. M., Pan, Y., Sheng, M., Yago, T., Silasi-Mansat, R., McGee, S., May, F., Nieswandt, B., Morris, A. J., Lupa, F., Coughlin, S. R., McEvoy, B. P., Chen, H., Kahl, M. N., and Xia, L. (2013) Podoplanin maintains high endothelial venule integrity by interacting with platelet CLEC-2. *Nature* **502**, 105–109.

20. Cueni, L. N., Chen, L., Zhang, H., Marino, D., Huggenberger, R., Alitalo, A., Bianchi, R., and Detmar, M. (2010) Podoplanin-Fc reduces lymphatic vessel formation in *in vitro* and *in vivo* and causes disseminated intravascular coagulation when transgenically expressed in the skin. *Blood* **116**, 4376–4384.

21. Kato, Y., Fujita, N., Kunita, A., Sato, S., Kaneko, M., Osawa, M., and Tsuru, T. (2003) Molecular identification of Aggrus/T1α as a platelet aggregation-inducing factor expressed in colorectal tumors. *J. Biol. Chem.* **278**, 51599–51605.

22. Zuberbühler, K., Palumbo, A., Bacci, C., Giovanni, S., Sommariva, R., Kaspar, M., Trachsel, E., and Neri, D. (2009) A general method for the selection of high-level scFv and IgG antibody expression by stably transfected mammalian cells. *Protein Eng. Des. Sel.* **22**, 169–174.

23. Pyz, E., and Brown, G. D. (2011) Screening for ligands of C-type lectin-like receptors. *Methods Mol. Biol.* **748**, 1–19.

24. Kerrigan, A. M., Navarro-Nuñez, L., Pyz, E., Finney, B. A., Willment, J. A., Watson, S. P., and Brown, G. D. (2012) Podoplanin-expressing inflammatory macrophages activate murine platelets via CLEC-2. *J. Thromb. Haemost.* **10**, 484–486.

25. Pyz, E., Huyssen, C., Marshall, A. S., Gordon, S., Taylor, P. R., and Brown, G. (2008) Characterisation of murine MICL (CLEC12A) and evidence for an endogenous ligand. *Eur. J. Immunol.* **38**, 1157–1163.

26. Varak-Hofer, I., Amstutz, H. P., Haldemann, A., Blaser, K., Morgenstaller, J. J., Bläumenstein, P., and Schubiger, P. A. (1992) Radioimmunolocalization of neuroblastoma xenografts with chimeric antibody cChE7. *J. Nucl. Med.* **33**, 231–236.

27. Vigil, B., Aebischer, D., Nitschke, M., Iolyeva, M., Röthlin, T., Antsiferova, O., and Hämmerling, J. J., Bläumenstein, P., and Schubiger, P. A. (1992) Radioimmunolocalization of neuroblastoma xenografts with chimeric antibody cChE7. *J. Nucl. Med.* **33**, 231–236.

28. Williams, M. C., Cao, Y., Hinds, A., Di Blasi, C., Silberhuber, G., Laakkonen, P., Petrova, T. R., Langer, B., and Raab, I. (2004) Lymphatic neoangiogenesis in human kidney transplants is associated with immunologically active lymphatic infiltrates. *J. Am. Soc. Nephrol.* **15**, 603–612.

29. Kerjaschki, D., Regele, H. M., Moosberger, I., Nagy-Bojarski, K., Watschinger, B., Soleiman, A., Birner, P., Krieger, S., Hovorka, A., Silberhuber, G., Laakkonen, P., Petrova, T. R., Langer, B., and Raab, I. (2004) Lymphatic neoangiogenesis in human kidney transplants is associated with immunologically active lymphatic infiltrates. *J. Am. Soc. Nephrol.* **15**, 603–612.

30. Kerjaschki, D., Regele, H. M., Moosberger, I., Nagy-Bojarski, K., Watschinger, B., Soleiman, A., Birner, P., Krieger, S., Hovorka, A., Silberhuber, G., Laakkonen, P., Petrova, T. R., Langer, B., and Raab, I. (2004) Lymphatic neoangiogenesis in human kidney transplants is associated with immunologically active lymphatic infiltrates. *J. Am. Soc. Nephrol.* **15**, 603–612.
megakaryocytic/platelet lineage are essential for development. Blood 119, 1747–1756
40. Osada, M., Inoue, O., Ding, G., Shirai, T., Ichise, H., Hirayama, K., Takano, K., Yatomi, Y., Hirashima, M., Fujii, H., Suzuki-Inoue, K., and Ozaki, Y. (2012) Platelet activation receptor CLEC-2 regulates blood/lymphatic vessel separation by inhibiting proliferation, migration, and tube formation of lymphatic endothelial cells. J. Biol. Chem. 287, 22241–22252
41. Kaneko, M., Kato, Y., Kunita, A., Fujita, N., Tsuruo, T., and Osawa, M. (2004) Functional sialylated O-glycan to platelet aggregation on Aggrus (T1α/Podoplanin) molecules expressed in Chinese hamster ovary cells. J. Biol. Chem. 279, 38838–38843